Given the cardio-renoprotective effects of SGLT2 inhibitors, the addition of SGLT2 inhibitors while reducing ESA requirements is expected to reduce the risk of cardiovascular complications in high-risk patients, while achieving good anemia control. Here, SLC5A2 is linked to anemia (phenotype).